SCHEMBL7052400

SCHEMBL7052400

CCOC(=O)C(CCc1ccccc1)(C[PH](=O)COS(=O)(=O)c1ccc(C)cc1)OCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.37
LMNA P02545 2/20 0.35
STAT3 P40763 1/20 0.35
GAA P10253 2/20 0.34
PKM P14618 1/20 0.34
FKBP1A P62942 1/20 0.34
PLAU P00749 1/20 0.34
HPN P05981 1/20 0.34
TSHR P16473 2/20 0.34
CNR2 P34972 1/20 0.34
MAPT P10636 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
THRB P10828 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
ALDH1A1 P00352 1/20 0.33
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7051779 0.94 FKBP1A (0.37) POLBLMNASTAT3GAAPKM
SCHEMBL7050906 0.90 ALDH1A1 (0.38) POLBLMNASTAT3GAATSHR
SCHEMBL7054000 0.87 ALDH1A1 (0.36) LMNATSHRMAPTCYP2D6CYP2C9
SCHEMBL7238354 0.82 ALDH1A1 (0.37) POLBLMNASTAT3GAATSHR
SCHEMBL7050155 0.81 PTPRC (0.35) POLBLMNAMAPTTHRBALDH1A1
SCHEMBL7048017 0.81 ENPP3 (0.37) POLBLMNASTAT3PLAUHPN
SCHEMBL7049813 0.80 ALDH1A1 (0.40) LMNAGAATSHRMAPTTHRB
SCHEMBL7050935 0.77 ALDH1A1 (0.42) POLBLMNAGAATSHRCYP2D6
SCHEMBL7049848 0.76 ALDH1A1 (0.36) LMNAMAPTCYP2D6CYP2C9CYP2C19
SCHEMBL9067917 0.74 ALDH1A1 (0.41) POLBLMNAGAAFKBP1APLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 POLB 1268/4885LMNA 488/4885STAT3 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.